DOC

• Total same-store Adjusted NOI grew 1.8% year-over-year, with Outpatient Medical up 2.5%, Lab down 3.2%, and Senior Housing up 19.2%.
• Healthpeak increased full-year 2026 diluted EPS guidance to $0.48-$0.52 and FFO as Adjusted per share to $1.73-$1.77.
• In July 2026, Healthpeak closed a joint venture with Brookfield, selling a 49% interest in an 86-property outpatient medical portfolio for approximately $1.025 billion.
• The Board authorized a new $500 million share repurchase program, and a monthly dividend of $0.10167 per share was declared for Q3 2026.

2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Janus Living completed its IPO in March 2026, generating approximately $880 million in net proceeds; Healthpeak owns 81.6%.
• Full-year 2026 diluted EPS guidance raised to $0.46–$0.50, Nareit FFO to $1.68–$1.72, and FFO as Adjusted to $1.71–$1.75.
• Same-store cash (adjusted) NOI growth was 0.0% for Q1 2026; full-year guidance reaffirmed at (1.0%)–1.0%.
• In April 2026, Healthpeak repurchased 5.9 million shares for approximately $100 million.

2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• All nine director nominees were elected, each receiving majority support; the Board was reduced to nine members immediately after the meeting.
• Director support ranged from 96.4% (Katherine M. Sandstrom) to 99.8% (John T. Thomas and Richard A. Weiss).
• The advisory vote on 2025 executive compensation passed with 89.2% of votes cast in favor.
• The ratification of Deloitte & Touche LLP as independent auditor for fiscal year 2026 was approved with 97.2% support.

5.07 Submission of Matters to a Vote of Security Holders

• The Healthpeak Term Loan Amendment established a $400.0 million senior unsecured delayed draw term loan facility with a five-year maturity.
• Maximum borrowing capacity under the Healthpeak Term Loan Credit Agreement increased from $1.5 billion to $2.0 billion.
• The Revolver Amendment and Physicians Realty Term Loan Amendment did not change maturity dates, pricing, or outstanding commitments.
• The amendments provide lender consent to the Janus IPO and related transactions.

1.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 9.01 Financial Statements and Exhibits

• Healthpeak Properties, Inc. announced that President and CEO Scott Brinker will present at the Citi 2026 Global Property CEO Conference on Tuesday, March 3, 2026, at 9:35 a.m. Eastern Time.
• A replay of the presentation will be available on Healthpeak's website through March 2, 2027.
• The disclosure was made under Item 7.01 Regulation FD Disclosure.

7.01 Regulation FD Disclosure

• Total Merger-Combined Same-Store Cash (Adjusted) NOI grew 3.9% in Q4 and 4.0% for full year 2025.
• Plans IPO of Janus Living, a senior housing REIT, to unlock value; targets $1 billion of asset sales, recapitalizations, and loan repayments in 2026.
• Acquired Gateway Crossing campus in South San Francisco for $600 million and bought out JV partner's 46.5% interest in 19 senior housing communities for $314 million.
• Declared monthly dividend of $0.10167 per share for Jan, Feb, Mar 2026, totaling $0.305 per share for Q1 and $1.22 annualized.

2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• For Q3 2025, diluted net loss was $0.17 per share, Nareit FFO was $0.45 per share, FFO as Adjusted was $0.46 per share, and AFFO was $0.42 per share.
• The company reaffirmed 2025 guidance for Nareit FFO per share of $1.78-$1.84, FFO as Adjusted per share of $1.81-$1.87, and same-store NOI growth of 3.0%-4.0%.
• Updated 2025 diluted EPS guidance to $0.00-$0.06, down from $0.25-$0.31.
• Board declared monthly dividends of $0.10167 per share for October, November, and December 2025, totaling $0.305 per share for Q4.

2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• On August 14, 2025, Healthpeak OP, LLC completed an underwritten offering of $500.0 million aggregate principal amount of 4.750% senior notes due 2033.
• Proceeds will be used to repay commercial paper borrowings and for general corporate purposes, including potential debt repayment, working capital, acquisitions, and capital expenditures.
• The notes are fully and unconditionally guaranteed on a joint and several basis by Healthpeak Properties, Inc., DOC DR Holdco, LLC, and DOC DR, LLC.
• The notes mature on January 15, 2033, with semi-annual interest payments beginning January 15, 2026, and are redeemable at Healthpeak OP's option under specified terms.

8.01 Other Events · 9.01 Financial Statements and Exhibits